During the preparation of this manuscript, the FDA has granted orphan drug designation (ODD) for DSP-0390, a newly developed inhibitor of EBP (https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-dsp-0390-in-brain-cancer, accessed on 19 July 2022), for which a phase I clinical trial for treating recurrent high-grade gliomas has been initiated (NCT05023551) [115]. This evidence concerns the gene EBP and central nervous system cancer.